Leg Veins
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Fitzpatrick CompanyON - Waterloo
2 programs2
Right leg treated with Glycerin compounded with 1% Lidocaine and EpinephrinePhase 41 trial
air coolingPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Fitzpatrick CompanyRight leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
Fitzpatrick Companyair cooling
Clinical Trials (2)
Total enrollment: 40 patients across 2 trials
NCT07342413Fitzpatrick CompanyRight leg treated with Glycerin compounded with 1% Lidocaine and Epinephrine
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Start: Feb 2026Est. completion: Jul 202620 patients
Phase 4Not Yet Recruiting
The Effect of Cooling on Sclerotherapy Efficacy
Start: Jan 2020Est. completion: Dec 202220 patients
Phase 4Unknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.